Soliris (eculizumab) shows effectiveness in treating patients with atypical hemolytic uremic syndrome (aHUS) both with and without severe and life-threatening hypertension, or high blood pressure, a large retrospective study found. Further, the researchers noted, “the results confirm the high [worse] severity and poor prognosis of untreated aHUS,” with a…
News
COVID-19 was a strong trigger for relapses of atypical hemolytic uremic syndrome (aHUS) in two brothers who were genetically predisposed to the syndrome, a recent case study reports. In both cases, treatment with Soliris (eculizumab) was effective in alleviating symptoms when given in the early stages of…
A booster dose of Moderna’s COVID-19 vaccine appears to have triggered an exaggerated immune response in a 38-year-old woman, leading to the development of atypical hemolytic uremic syndrome (aHUS), a case study reported. Researchers stressed the importance of reporting serious side effects after a COVID-19 vaccine so as to…
A new mutation in the CD46 gene linked to recurrent atypical hemolytic uremic syndrome (aHUS) was identified in a 13-month-old girl, according to a case report from Denmark. As described in the report, the mutation affected the activity of the complement cascade — a part of the immune system…
“Awareness through Togetherness” is the theme for supporters around the world to mark this year’s aHUS Awareness Day, on Sept. 24. The 8th annual event seeks to call attention to atypical hemolytic uremic syndrome (aHUS) and the needs of the community, as well as to spotlight advancements in research…
Sirnaomics has launched preclinical testing of a first candidate therapy developed with its GalAhead platform for complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS). The therapy, STP144G, is one of four experimental treatments developed with the proprietary Sirnaomics platform. Data from these early studies are expected to eventually…
COVID-19 might have triggered a relapse of atypical hemolytic uremic syndrome (aHUS) in a 36-year-old woman, according to a recent case report. Despite treatment with Soliris (eculizumab), the patient ultimately died. However, a literature review conducted by study authors revealed nine other cases of COVID-19-associated aHUS and showed…
After the successful treatment with Soliris (eculizumab) of a 20-year-old man experiencing a flare-up of atypical hemolytic uremic syndrome (aHUS), his medical team called for the therapy to be made available to all aHUS patients, despite its high cost. “[Soliris] should be started early if plasmapheresis [plasma exchange…
Soliris (eculizumab) safely and effectively treated chronic kidney disease in children with atypical hemolytic uremic syndrome (aHUS), a review study confirmed. Researchers suggested that more research is necessary, however, to establish its effectiveness, safety, and time of discontinuation in the long term. The review study, “The treatment…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases have been selected to receive a Horizon Therapeutics‘ #RAREis Global Advocate Grant. Winners of this year’s inaugural awards are spread across nine countries and represent a total of 29 rare…
Recent Posts
- Team care saves mother with trio of postpartum complications
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse
- For women like me, hair loss can be particularly devastating
- aHUS drugs restore kidney function in 60% of patients in Romania
- aHUS has changed my life in drastic and unexpected ways
- Rare lupus nephritis–aHUS case improves after Soliris treatment
- How my young children had to adapt to having a sick parent
- Early Soliris use boosts kidney recovery, cuts dialysis need in aHUS
- Dual therapy benefits man with aHUS, Castleman disease